When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

Lauren E Cain; Roger Logan; James M Robins; Jonathan A C Sterne; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; Ard van Sighem; Frank de Wolf; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casabona; Julia del Amo; Santiago Moreno; Remonie Seng; Laurence Meyer; Santiago Perez-Hoyos; Roberto Muga; Sara Lodi; Emilie Lanoy; Dominique Costagliola; Miguel A Hernan; HIV-CAUSAL Collaboration

doi:10.7326/0003-4819-154-8-201104190-00001

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

Lauren E Cain, Roger Logan, James M Robins, Jonathan A C Sterne, Caroline Sabin, Loveleen Bansi, Amy Justice, Joseph Goulet, Ard van Sighem, Frank de Wolf, Heiner C Bucher, Viktor von Wyl, Anna Esteve, Jordi Casabona, Julia del Amo, Santiago Moreno, Remonie Seng, Laurence Meyer, Santiago Perez-Hoyos, Roberto MugaSara Lodi, Emilie Lanoy, Dominique Costagliola, Miguel A Hernan, HIV-CAUSAL Collaboration

Research output: Contribution to journal › Article (Academic Journal) › peer-review

214 Citations (Scopus)

Abstract

Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.

Original language	English
Pages (from-to)	509-515
Number of pages	7
Journal	Annals of Internal Medicine
Volume	154
Issue number	8
DOIs	https://doi.org/10.7326/0003-4819-154-8-201104190-00001
Publication status	Published - 19 Apr 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7326/0003-4819-154-8-201104190-00001

http://annals.org/article.aspx?articleid=746932

Handle.net

Persistent link

ART-CC: Prognosis of HIV-infected patients treated with ART
Sterne, J. A. C. (Principal Investigator), Ingle, S. M. (Researcher) & May, M. T. (Co-Principal Investigator)
1/02/12 → 1/02/15
Project: Research
THE IMPACT OF HIGHLY EFFECTIVE ANTIRETROVIRAL THERAPY: MONITORING AND MODELLING BENEFIT AND HARM
Sterne, J. A. C. (Principal Investigator)
1/02/02 → 1/02/08
Project: Research

Cite this

Cain, L. E., Logan, R., Robins, J. M., Sterne, J. A. C., Sabin, C., Bansi, L., Justice, A., Goulet, J., van Sighem, A., de Wolf, F., Bucher, H. C., von Wyl, V., Esteve, A., Casabona, J., del Amo, J., Moreno, S., Seng, R., Meyer, L., Perez-Hoyos, S., ... HIV-CAUSAL Collaboration (2011). When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals of Internal Medicine, 154(8), 509-515. https://doi.org/10.7326/0003-4819-154-8-201104190-00001

@article{4b121b2a459b4e2b9d01611c7c836428,

title = "When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study",

abstract = "Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.",

author = "Cain, \{Lauren E\} and Roger Logan and Robins, \{James M\} and Sterne, \{Jonathan A C\} and Caroline Sabin and Loveleen Bansi and Amy Justice and Joseph Goulet and \{van Sighem\}, Ard and \{de Wolf\}, Frank and Bucher, \{Heiner C\} and \{von Wyl\}, Viktor and Anna Esteve and Jordi Casabona and \{del Amo\}, Julia and Santiago Moreno and Remonie Seng and Laurence Meyer and Santiago Perez-Hoyos and Roberto Muga and Sara Lodi and Emilie Lanoy and Dominique Costagliola and Hernan, \{Miguel A\} and \{HIV-CAUSAL Collaboration\}",

year = "2011",

month = apr,

day = "19",

doi = "10.7326/0003-4819-154-8-201104190-00001",

language = "English",

volume = "154",

pages = "509--515",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "8",

}

Cain, LE, Logan, R, Robins, JM, Sterne, JAC, Sabin, C, Bansi, L, Justice, A, Goulet, J, van Sighem, A, de Wolf, F, Bucher, HC, von Wyl, V, Esteve, A, Casabona, J, del Amo, J, Moreno, S, Seng, R, Meyer, L, Perez-Hoyos, S, Muga, R, Lodi, S, Lanoy, E, Costagliola, D, Hernan, MA & HIV-CAUSAL Collaboration 2011, 'When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study', Annals of Internal Medicine, vol. 154, no. 8, pp. 509-515. https://doi.org/10.7326/0003-4819-154-8-201104190-00001

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. / Cain, Lauren E; Logan, Roger; Robins, James M et al.
In: Annals of Internal Medicine, Vol. 154, No. 8, 19.04.2011, p. 509-515.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

AU - Cain, Lauren E

AU - Logan, Roger

AU - Robins, James M

AU - Sterne, Jonathan A C

AU - Sabin, Caroline

AU - Bansi, Loveleen

AU - Justice, Amy

AU - Goulet, Joseph

AU - van Sighem, Ard

AU - de Wolf, Frank

AU - Bucher, Heiner C

AU - von Wyl, Viktor

AU - Esteve, Anna

AU - Casabona, Jordi

AU - del Amo, Julia

AU - Moreno, Santiago

AU - Seng, Remonie

AU - Meyer, Laurence

AU - Perez-Hoyos, Santiago

AU - Muga, Roberto

AU - Lodi, Sara

AU - Lanoy, Emilie

AU - Costagliola, Dominique

AU - Hernan, Miguel A

AU - HIV-CAUSAL Collaboration

PY - 2011/4/19

Y1 - 2011/4/19

N2 - Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.

AB - Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.

U2 - 10.7326/0003-4819-154-8-201104190-00001

DO - 10.7326/0003-4819-154-8-201104190-00001

M3 - Article (Academic Journal)

C2 - 21502648

SN - 0003-4819

VL - 154

SP - 509

EP - 515

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 8

ER -

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Projects

ART-CC: Prognosis of HIV-infected patients treated with ART

THE IMPACT OF HIGHLY EFFECTIVE ANTIRETROVIRAL THERAPY: MONITORING AND MODELLING BENEFIT AND HARM

Cite this